Peter Lee, MD
Nephrology · Los Angeles, CANPI 1932237013
Payments from drug & device makers
Across 198 payments — averaging $142.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$21K
- Bayer$1K
- Akebia Therapeutics Inc$849
- AstraZeneca$846
- Amgen$820
- Ardelyx, Inc.$678
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$17,84063%
- Travel & lodging$2,0107%
- Food & beverage$8,22329%
- Education$2361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 34 | $21,089 |
| Bayer | 25 | $1,028 |
| Akebia Therapeutics Inc | 25 | $849 |
| AstraZeneca(2 entities) | 17 | $846 |
| Amgen(2 entities) | 21 | $820 |
| Ardelyx, Inc. | 14 | $678 |
| Vifor Pharma, Inc. | 13 | $621 |
| Otsuka America Pharmaceutical, Inc. | 7 | $381 |
| Boehringer Ingelheim | 4 | $297 |
| Boston Scientific | 2 | $251 |
| Mallinckrodt Hospital Products Inc. | 7 | $234 |
| Novartis | 5 | $152 |
| Travere Therapeutics, Inc. | 2 | $150 |
| Mallinckrodt Enterprises LLC | 1 | $147 |
| OPKO Pharmaceuticals, LLC | 5 | $127 |
| GSK | 1 | $111 |
| Jazz Pharmaceuticals Inc. | 1 | $110 |
| Fresenius USA Marketing, Inc. | 1 | $97 |
| Calliditas Therapeutics US Inc. | 3 | $71 |
| Baxter Healthcare | 2 | $70 |
| Lilly USA, LLC | 1 | $34 |
| Nuwellis, Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| AbbVie | 1 | $25 |
| Merck | 1 | $20 |
| Novo Nordisk | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
| Dentsply Sirona Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,309 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 189 | $125,168 |
| TradjentaLinagliptin | 180 | $97,619 |
| ProcritEpoetin Alfa | 75 | $73,595 |
| RenvelaSevelamer Carbonate | 45 | $56,455 |
| KerendiaFinerenone | 84 | $52,692 |
| VascepaIcosapent Ethyl | 121 | $45,674 |
| ZenpepLipase/Protease/Amylase | 26 | $26,804 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $22,800 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $21,212 |
| AuryxiaFerric Citrate | 15 | $20,325 |
| CreonLipase/Protease/Amylase | 21 | $17,959 |
| JanuviaSitagliptin Phosphate | 44 | $17,290 |
| JentaduetoLinagliptin/Metformin Hcl | 24 | $12,550 |
| Sevelamer Carbonate | 62 | $10,135 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $6,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $297 | $235,337393 claims |
| Johnson & JohnsonProcrit | $13 | $73,59575 claims |
| BayerKerendia | $1,028 | $52,69284 claims |
| AstraZenecaLokelma | $846 | $21,21227 claims |
| Akebia Therapeutics IncAuryxia | $849 | $20,32515 claims |
| AbbVieCreon | $25 | $17,95921 claims |
| MerckJanuvia | $20 | $17,29044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.